1. Home
  2. GH vs KD Comparison

GH vs KD Comparison

Compare GH & KD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$101.86

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Logo Kyndryl Holdings Inc.

KD

Kyndryl Holdings Inc.

HOLD

Current Price

$26.84

Market Cap

5.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
KD
Founded
2011
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
14.1B
5.8B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
GH
KD
Price
$101.86
$26.84
Analyst Decision
Strong Buy
Buy
Analyst Count
21
5
Target Price
$82.76
$39.60
AVG Volume (30 Days)
2.2M
2.0M
Earning Date
10-29-2025
02-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.68
Revenue
$902,569,000.00
$15,008,000,000.00
Revenue This Year
$34.72
$6.40
Revenue Next Year
$26.46
$3.60
P/E Ratio
N/A
$16.03
Revenue Growth
30.38
N/A
52 Week Low
$29.91
$23.28
52 Week High
$112.43
$44.20

Technical Indicators

Market Signals
Indicator
GH
KD
Relative Strength Index (RSI) 55.40 54.31
Support Level $100.21 $25.82
Resistance Level $109.59 $27.84
Average True Range (ATR) 4.22 0.68
MACD -1.65 0.34
Stochastic Oscillator 13.51 72.05

Price Performance

Historical Comparison
GH
KD

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About KD Kyndryl Holdings Inc.

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.

Share on Social Networks: